RAGE Activation by S100P in Colon Cancer Stimulates Growth, Migration, and Cell Signaling Pathways

Fuentes, Maren K.; Nigavekar, Shraddha S.; Arumugam, Thiruvengadam; Logsdon, Craig D.; Schmidt, Ann Marie; Park, Juliet C.; Huang, Emina H.

doi:10.1007/s10350-006-0850-5

Cited by 140 publications

(143 citation statements)

References 34 publications

Supporting

Mentioning

134

Contrasting

Order By: Relevance

“…We found that S100P protein and mRNA was expressed in 2/3 CRC tissues while only a few paired control tissues were positive for S100P, this was consistent with previous studies (19)(20)(21). In our group of CRC patients, all the 11 cases with stage IV died within 3 years after resection, thus, we analyzed CRC patients of stages I to III, the data showed that patients with S100P-positive tumors had unfavorable prognosis.…”

Section: Discussionsupporting

confidence: 90%

“…S100P could promote the proliferation, migration, and invasion of pancreatic cancer cell via a receptor for activated glycation end products (28), it also stimulated colon cancer cell proliferation and migration in vitro (20,21), and lung cancer cells in an autocrine manner (26,29). These findings may, at least partially, provide molecular insight into the relationship of S100P and prognosis in cancers.…”

Section: Discussionmentioning

confidence: 75%

“…S100P expression was associated with the grade of tumors, and it promoted tumor invasion and metastasis (14,17,18). Expression of S100P was shown in CRC tissues compared with much less expression in normal mucosa (19)(20)(21), and it stimulated cancer cell growth and migration in vitro (20,21). It is conceivable to speculate that S100P might be correlated with the development and the progression of CRC as well as the prognosis of patients with CRC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

S100P, a potential novel prognostic marker in colorectal cancer

et al. 2012

View full text Add to dashboard Cite

Abstract. Previous studies have shown that S100P contributes to the development of a number of tumors. However, its prognostic significance in colorectal cancer (CRC) has not been demonstrated. This study aimed to confirm the expression of S100P in colorectal cancer as well as the epigenetic mechanism underlying its gene expression, and to demonstrate whether S100P could be used to predict prognosis as a biomarker. We tested the expression of S100P in 96 CRCs and their paired tissue controls, as well as 13 colon cancer cell lines by RT-PCR and western blotting. Expression of the S100P protein and mRNA was significantly higher in cancerous regions compared to that in paired non-cancerous tissues (P=4.59x10 -17 , 0.005 respectively). The expression was significantly correlated with the hypomethylation of the S100P promoter (P=4.92x10 -5 ), which was detected by bisulphite sequencing PCR (BSP) and quantitative methylation-specific real-time PCR (QMSP). In stages I to III, the patients with positive expression of S100P protein showed poorer overall survival compared to those with S100P negative expression, P= 0.031. We also measured the preoperative serum S100P levels by ELISA. The patients with normal serum levels of S100P showed favorable prognosis compared with patients with elevated S100P levels (P=0.008). These data suggest that S100P protein may be a potential novel prognostic biomarker in CRC patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

S100P, a potential novel prognostic marker in colorectal cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…However, in contrast to the expression in lung cancers, RAGE was also upregulated in colon cancer tissues (10). As a result, it was challenging to apply the simple ligand/receptor binding and degradation theory as an explanation for the phenomena of RAGE expression.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have indicated that RAGE expression is also closely associated with the invasive and metastatic activity of cancer, including gastric (9) and colon cancer (10). Upregulation of RAGE has been identified in breast (11), colon and pancreatic cancers (12), but downregulation of the expression of RAGE and sRAGE has been reported in lung and esophageal cancer (12,13).…”

Section: Introductionmentioning

confidence: 99%

Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Wang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Receptor for advanced glycation end products (RAGE) is associated with the pathogenesis of cancer progression. The pathological effects mediated through RAGE are physiologically inhibited by soluble RAGE (sRAGE). The aim of the present study was to identify the expression of the sRAGE, RAGE and RAGE ligands in serum samples and lung cancer tissue obtained from lung cancer patients. Using ELISA and immunohistochemistry, it was observed that the sRAGE levels were downregulated in the serum, the expression of RAGE was decreased in the lung cancer tissue and the RAGE ligands HMGB1 and S100 were upregulated in cancer tissue. Furthermore, the presence of several selected types of RAGE polymorphism that occur in lung cancers were measured in the tissue samples. An association between the -429T/C and 2184A/G polymorphisms of RAGE and the genesis and progression of lung cancer was identified. The comparison between various histological subtypes and stages of lung cancer was performed with the aim to clarify the biological role of the RAGE gene, and identify a biomarker to aid diagnosis and predict the prognosis for lung cancer patients.

show abstract

Inflammation and Microbiota and Gut Reconditioning

Bengmark

2017

Inflammation - From Molecular and Cellular Mechanisms to the Clinic

View full text Add to dashboard Cite

RAGE Activation by S100P in Colon Cancer Stimulates Growth, Migration, and Cell Signaling Pathways

Cited by 140 publications

References 34 publications

S100P, a potential novel prognostic marker in colorectal cancer

S100P, a potential novel prognostic marker in colorectal cancer

Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Inflammation and Microbiota and Gut Reconditioning

Contact Info

Product

Resources

About